Shots:

•  Results of 2600 patients trial reported significant i.e. ≥50% reduction in migraine days with comparable safety and     tolerability to PBO
•  Aimovig works by blocking calcitonin gene-related peptide receptor (CGRP-R) which plays vital role in migraine
• Can be self-administered every four weeks with the Sure Click auto injector pen- device commonly used for different conditions
• Aimovig is already approved by FDA in May 17- followed by Australia and Swissmedic on July 3 & 13 respectively in 2018 with more expected approvals globally

      Ref: Novartis | Image: Forbes